Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Curr Probl Cardiol ; 49(9): 102664, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38789017

RESUMEN

PURPOSE: Despite effectiveness of sodium-glucose cotransporter 2 (SGLT 2) inhibitors, concerns have been raised about the potential side effects of these drugs. Thus, a pharmaco-vigilance study was designed that aims to identify any discrepancies between the reported adverse events & assess the safety profile of SGLT2 inhibitors. METHODS: We studied diabetic ketoacidosis (DKA), euglycemic DKA, amputation, urinary tract infection (UTI), mycotic genital infection & hypotension associated with empagliflozin, dapagliflozin, canagliflozin & ertugliflozin in RCTs and reporting databases. WHO's VigiBase, FAERS, EMA's EudraVigilance & DAEN were thoroughly studied to obtain spontaneously reported real-world adverse events. RESULTS: Different SGLT2 inhibitors exhibit varied side effect profiles. Additionally, the findings suggest that adverse events may be more likely to occur in a broader population in the real world than in a highly inclusive clinical trial subset CONCLUSION: Our study provides comparison of the real world reported adverse events to adverse events reported in the clinical trials studying the efficacy of SGLT 2 inhibitors.


Asunto(s)
Farmacovigilancia , Ensayos Clínicos Controlados Aleatorios como Asunto , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Humanos , Inhibidores del Cotransportador de Sodio-Glucosa 2/efectos adversos , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Sistemas de Registro de Reacción Adversa a Medicamentos , Compuestos de Bencidrilo/efectos adversos , Compuestos de Bencidrilo/uso terapéutico , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/uso terapéutico , Canagliflozina/efectos adversos , Canagliflozina/uso terapéutico , Glucósidos/efectos adversos , Glucósidos/uso terapéutico
2.
Cureus ; 15(6): e40707, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37485137

RESUMEN

Cocaine-associated coronary artery disease and ST-segment elevation myocardial infarction (STEMI) have been well described in the literature. However, very few cases of cocaine-induced multivessel coronary artery disease have been reported. We report a very rare case of cocaine-associated triple vessel coronary artery disease in a 41-year-old male patient. The patient underwent urgent catheterization that revealed occlusion of his proximal left anterior descending artery (LAD), mid-circumflex artery, and right coronary artery with angioplasty and stent placement. His hospitalization course was complicated by cardiogenic shock, shock liver, acute renal failure, and sepsis.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA